|Awarded On||March 29, 2012|
|Title||Development Of Multistage Vectored siRNA Therapeutics For The Treatment Of Breast Cancer|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The Methodist Hospital Research Institute|
|Principal Investigator/Program Director||Mauro Ferrari|
While substantial progress has been recorded in the fight against breast cancer, the burden of death and suffering inflicted upon society by this disease remain unacceptably high. In 2010, an estimated 207,090 newcases of invasive breast cancer are expected in women in the U. S. About 39,840 women in U. S. are expected to die from breast cancer this year. Accounting for around 15% of total breast cancer cases, triple negative breast cancer (TNBC) primarily affects younger women – untypical for breast cancer in general – women with African-American descent and women carrying a BRCA1 mutation and others. The current treatments with chemotherapy drugs are not very effective. Major reasons for t...